| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
QURE
uniQure
|
Jun 17, 2026 | BUY |
Strong Buy
+16.1% avg upside
29 analysts
|
— | · |
|
AXSM
Axsome Therapeutics
|
Jun 17, 2026 | BUY |
Strong Buy
-10.5% avg upside
28 analysts
|
$300.00
19.79% Upside
|
· |
|
NTLA
Intellia Therapeutics
|
Jun 14, 2026 | BUY |
Strong Buy
+151.9% avg upside
37 analysts
|
— | · |
|
JAZZ
Jazz Pharmaceuticals
|
Jun 12, 2026 | BUY |
Strong Buy
-1.8% avg upside
35 analysts
|
$275.00
22.39% Upside
|
-2.6% |
|
NGEN
NervGen Pharma
|
Jun 11, 2026 | BUY |
Strong Buy
+358.4% avg upside
8 analysts
|
— | · |
|
DRUG
Bright Minds Biosciences
|
May 20, 2026 | BUY |
Strong Buy
+120.9% avg upside
10 analysts
|
— | +0.9% |
|
UTHR
United Therapeutics
|
May 17, 2026 | BUY |
Strong Buy
-18.7% avg upside
26 analysts
|
$675.00
25.81% Upside
|
-5.4% |
|
MPLT
MapLight Therapeutics, Inc.
|
May 14, 2026 | BUY |
Strong Buy
+33.6% avg upside
11 analysts
|
— | -7.3% |
|
ANAB
AnaptysBio
|
May 13, 2026 | BUY |
Strong Buy
+26.1% avg upside
26 analysts
|
$75.00
30.42% Upside
|
-8.1% |
|
MGX
Metagenomi, Inc.
|
May 11, 2026 | BUY |
Strong Buy
+733.4% avg upside
7 analysts
|
— | -5.2% |
|
PTCT
PTC Therapeutics
|
May 08, 2026 | BUY |
Buy
-1.5% avg upside
29 analysts
|
$90.00
13.86% Upside
|
+6.6% |
|
DNLI
Denali Therapeutics
|
May 08, 2026 | BUY |
Strong Buy
+60.2% avg upside
24 analysts
|
— | +11.8% |
|
TRDA
Entrada Therapeutics Inc
|
May 07, 2026 | BUY |
Strong Buy
+198.5% avg upside
10 analysts
|
— | -0.6% |
|
XENE
Xenon
|
May 07, 2026 | BUY |
Strong Buy
+19.0% avg upside
28 analysts
|
— | -6.4% |
|
MIRM
Mirum Pharmaceuticals
|
May 07, 2026 | BUY |
Strong Buy
+7.0% avg upside
21 analysts
|
$145.00
35.38% Upside
|
+4.1% |
|
PRME
Prime Medicine, Inc.
|
May 07, 2026 | BUY |
Strong Buy
+209.6% avg upside
16 analysts
|
— | -1.8% |
|
RAPP
Rapport Therapeutics, Inc.
|
May 07, 2026 | BUY |
Strong Buy
+45.9% avg upside
12 analysts
|
— | -7.7% |
|
AMLX
Amylyx Pharmaceuticals Inc
|
May 05, 2026 | BUY |
Strong Buy
+46.8% avg upside
13 analysts
|
— | -7.2% |
|
VRDN
Viridian Therapeutics
|
May 05, 2026 | BUY |
Strong Buy
+103.7% avg upside
32 analysts
|
— | -14.1% |
|
ARWR
Arrowhead Pharmaceuticals
|
May 05, 2026 | BUY |
Strong Buy
-19.2% avg upside
26 analysts
|
— | -0.5% |
|
ALKS
Alkermes
|
May 05, 2026 | BUY |
Strong Buy
-17.6% avg upside
34 analysts
|
$42.00
6.62% Downside
|
+25.1% |
|
ARDX
Ardelyx
|
Apr 30, 2026 | BUY |
Strong Buy
+124.0% avg upside
21 analysts
|
$13.00
114.91% Upside
|
-12.5% |
|
MCRB
Seres Therapeutics
|
Nov 05, 2025 | BUY |
Buy
+162.2% avg upside
10 analysts
|
— | -40.2% |
|
JBIO
Jade Biosciences
|
Jul 19, 2024 | HOLD |
Strong Buy
+232.9% avg upside
16 analysts
|
— | -84.4% |
|
ESPR
Esperion
|
Jan 12, 2024 | HOLD |
Buy
+701.2% avg upside
22 analysts
|
— | -22.5% |
|
EVLO
Evelo Biosciences
|
Oct 17, 2023 | HOLD |
Buy
+4499999900.0% avg upside
5 analysts
|
— | · |
|
PTC
PTC
|
May 24, 2023 | HOLD |
Strong Buy
+32.6% avg upside
31 analysts
|
$40.00
65.15% Downside
|
+40.4% |
|
HLIT
Harmonic
|
Oct 10, 2022 | BUY |
Buy
-13.5% avg upside
14 analysts
|
— | -30.5% |
|
PVLA
Palvella Therapeutics
|
Oct 01, 2020 | BUY |
Strong Buy
+45.3% avg upside
27 analysts
|
— | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.